Výsledky vyhledávání

Report

Identification of a Novel NRG1 Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report.

Autor: Mitchell SG; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Emory University School of Medicine, Atlanta, GA, USA., Basu GD; Ashion Analytics, Phoenix, AZ, USA., Eaton B; Emory University School of Medicine, Atlanta, GA, USA., Goodman LJ; Ashion Analytics, Phoenix, AZ, USA., Goldsmith KC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Emory University School of Medicine, Atlanta, GA, USA.

Publikováno v: Case reports in oncology [Case Rep Oncol] 2023 Apr 20; Vol. 16 (1), pp. 249-255. Date of Electronic Publication: 2023 Apr 20 (Print Publication: 2023).

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.

Autor: Vranic S; College of Medicine, QU Health, Qatar University, Doha, Qatar; Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. semir.vranic@gmail.com; svranic@qu.edu.qa., Basu GD; Exact Sciences, Phoenix, Arizona, United States of America., Hall DW; Exact Sciences, Phoenix, Arizona, United States of America., Gatalica Z; Exact Sciences, Phoenix, Arizona, United States of America; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Publikováno v: Acta medica academica [Acta Med Acad] 2022 Dec; Vol. 51 (3), pp. 217-231. Date of Electronic Publication: 2022 Dec 30.

Zobrazit plný text záznamu

Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.

Autor: Drenner K; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA., Basu GD; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Goodman LJ; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Ozols AA; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., LoBello JR; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Royce T; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Gordon MS; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Borazanci EH; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Steinbach MA; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Trent J; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA., Sharma S; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.

Publikováno v: Oncotarget [Oncotarget] 2022 Oct 20; Vol. 13, pp. 1174. Date of Electronic Publication: 2022 Oct 20.

Zobrazit plný text záznamu

Akademický článek

Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.

Autor: Summers RJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Castellino SM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Porter CC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., MacDonald TJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Basu GD; Exact Sciences, Phoenix, AZ., Szelinger S; Exact Sciences, Phoenix, AZ., Bhasin MK; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.; Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA., Cash T; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Carter AB; Department of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Atlanta, GA., Castellino RC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Fangusaro JR; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Mitchell SG; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Pauly MG; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Pencheva B; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Wechsler DS; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Graham DK; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Goldsmith KC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2022 Apr; Vol. 6, pp. e2100451.

Zobrazit plný text záznamu

Report

The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.

Autor: Drenner K; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.; These authors contributed equally to this work., Basu GD; Ashion Analytics, LLC, Phoenix, AZ 85004, USA.; These authors contributed equally to this work., Goodman LJ; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Ozols AA; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., LoBello JR; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Royce T; Ashion Analytics, LLC, Phoenix, AZ 85004, USA., Gordon MS; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Borazanci EH; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Steinbach MA; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Trent J; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA., Sharma S; Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.

Publikováno v: Oncotarget [Oncotarget] 2021 Aug 31; Vol. 12 (18), pp. 1836-1847. Date of Electronic Publication: 2021 Aug 31 (Print Publication: 2021).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání